Imaging agent developer Telix to buy RLS radiopharmaceutical network for up to $250M

Melbourne, Australia-based imaging agent developer Telix has reached a deal to acquire RLS (USA) Inc. for up to $250 million, the two announced Monday.

RLS operates America’s only Joint Commission-accredited radiopharmacy network, with 31 locations covering over 85% of the U.S. population. Headquartered in Lake Mary, Florida, RLS distributes PET and SPECT agents along with therapeutic radiopharmaceuticals, serving over 1,500 customers.